Whole body diffusion Magnetic resonance imaging, a diagnostic alternative in the evaluation and staging of patients with prostate cancer.
DOI:
https://doi.org/10.54212/27068048.v8i1.30Keywords:
Prostate cancer, metastases, whole body diffusion MRI, PET-CT.Abstract
Objective: To present the use of Whole Body Diffusion Magnetic Resonance Imaging (WB D MRI) as an accessible tool for the diagnosis of loco regional and remote metastasis in a patient with Prostate Cancer.
Material and Methods: the case of a private clinic patient and the studies carried out of Abdominal Computed Tomography (CT), Bone Scintigraphy, FDG PET Scan and WB D MRI for the diagnosis and staging of Metastatic Prostate Cancer are described.
Result: a 70-year-old male who presented Prostate Specific Antigen (PSA) of 16 ng / ml who underwent a prostate biopsy showing Prostate Adenocarcinoma Gleason 7 (4 + 7). Subsequently, he underwent radical prostatectomy in August 2017, varying the pathology result to Gleason 8, and after the elevation of the PSA at 2 months, Salvage Radiotherapy was given in November 2017. He presented PSA at low levels until January 2020, who consulted for have PSA 65 ng / ml, for which diagnostic and staging studies are carried out, which are described.
Discussion: Whole Body Diffusion MRI has better sensitivity and specificity than Bone Scintigraphy in detecting bone metastases from Prostate Cancer, better sensitivity than abdominal CT in detection of lymph node metastases and very similar with PET-CT.
Conclusions: The use of WBD MRI in patients with Prostate Cancer is a tool that can be used as a all in one image modality to diagnose bone, lymph node, and visceral metastases. Local comparative studies are recommended for validation.
Downloads
References
) Rosenkrantz, A. MRI of the prostate A practical approach 2017 Thieme Medical Publishers 1-3 https://doi.org/10.1055/b-0037-144967 DOI: https://doi.org/10.1055/b-0037-144967
) Pasoglou V, Larbi A, Collette L. et al One step TNM staging of high risk prostate cancer using magnetic resonance imaging (MRI): toward an upfront simplified "all in one" imaging approach ? Prostate 2014,74:469-477. https://doi.org/10.1002/pros.22764 DOI: https://doi.org/10.1002/pros.22764
) Mottet N. et al EAU-ESTRO-SIOG Guidelines on prostate cáncer, Part 1: screening, diagnosis and loal treatment with curative intention. Eur urol 2017;71:618-625. https://doi.org/10.1016/j.eururo.2016.08.003 DOI: https://doi.org/10.1016/j.eururo.2016.08.003
) Lecouvet FE, El Movedden J, Collette Can whole body magnetic resonance imaging with diffusion-weighted image replace Tc 99m bone scanning and computed tomography for single step detection of metastasis in patients with high risk prostate cancer ? Eur urol 2012;62(1):68-75. https://doi.org/10.1016/j.eururo.2012.02.020 DOI: https://doi.org/10.1016/j.eururo.2012.02.020
) Lecouvet FE, Simon M., Tombal B et al Whole body MRI versus axial skeleton MRI (AS-MRI) to detect and measure bone metastasis in prostate cancer (PCA) Eur Radiol 2010;20:2973-2982. https://doi.org/10.1007/s00330-010-1879-3 DOI: https://doi.org/10.1007/s00330-010-1879-3
) Kapur A, Jain N, Kapur A, Mahajan G. Is whole body-diffusion MRI an alternative to PET-CT A review of the literature. Clinics in Oncology 2017;2:1-5
) Shen G, Denj H, Hu S, Jia Z. Comparison of choline-PET/CT, MRI, SPECT and bone metastases in patients with prostate cancer: a meta-analysis. Skeletal radiol 2014;43:1503-1513. https://doi.org/10.1007/s00256-014-1903-9 DOI: https://doi.org/10.1007/s00256-014-1903-9
) Jambor I, Kuisma A., Ramedan S. Prospective evaluation of planer bone scintigraphy, SPECT, SPECT-CT, F-Na F, PET-CT and whole body MRI including diffusion for the detection of bone metastases in high risk breast and prostate cancer patients: SKELETA clinical trial. Acta oncològica 2016;55:59-67. https://doi.org/10.3109/0284186X.2015.1027411 DOI: https://doi.org/10.3109/0284186X.2015.1027411
) Woo S, Suh Ch, Kim SY et al Diagnostic performance of magnetic resonance imaging for the detection of bone metastasis in prostate cancer: A systematic review and meta-analysis. Eur urol 2018;73: 81-91. https://doi.org/10.1016/j.eururo.2017.03.042 DOI: https://doi.org/10.1016/j.eururo.2017.03.042
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2020 Rodolfo Ibarra, Hugo Arriaga
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License 4.0 that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
